Wednesday, March 12, 2014

Oxigene soars on ovarian cancer drug results

Oxigene inc more than doubled in after-hours trading after the biopharmaceutical company reported positive Phase 2 clinical trial results for an ovarian cancer treatment.



The company has a pipeline with various treatments under clinical studies that each aim to combine a compound known as zybrestat with other therapies to potentially treat ovarian and certain thyroid cancers.  Here is more on the ovarian cancer phase 2 results